Genetically engineered viruses that teach your immune system to kill…
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Kopra Bio is a San Francisco-based YC-backed biotechnology company developing non-lytic viral immunotherapy that turns cancer cells into local biofactories to stimulate anti-tumor immunity, with an initial focus on glioblastoma.
Primary product
Genetically engineered viral immunotherapy platform for solid tumors, initially glioblastoma
Founded
2024
Headquarters
San Francisco, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Viral immunotherapy / oncology
Offices
0 jobs at Kopra Bio
Check back later for new openings
Business model
Investors
Mission-driven, research-heavy biotech with a strong academic/UCSF origin story and YC backing; public materials emphasize scientific rigor, translational speed, and a high-unmet-need oncology focus.
Differentiators
Technology
Competitors
Estimated revenue
~$684K annual revenue (third-party estimate; roughly $500K-$1M range)
Estimated monthly visits
1.6K
Traffic estimate as of Jun 2026
Endpoints News · Jun 2026
Reported Kopra Bio's $9.1M seed round, the planned investigator-initiated trial in China, and the investor group including Y Combinator, Paul Graham, Metaplanet, Multimodal Ventures, Singularity Capital, Pioneer Fund, Mythos Ventures, Venn10 Capital, PNOC Foundation, and angels.
UCSF Innovation Ventures · Jun 2026
UCSF’s commercialization arm highlighted Kopra Bio's funding, the spinout origin, and the team around Manish Aghi, Noriyuki Kasahara, Alexander Haddad, and Sara Collins.
Nature Communications · May 2026
The research paper underpinning Kopra Bio describes a non-lytic replicating retrovirus delivering an IL-15 superagonist into glioblastoma cells and shows durable antitumor immunity in mouse models.
Charles River Laboratories · Dec 2025
Charles River named Kopra Bio to the second cohort of its Cell & Gene Therapy Incubator Program, describing the company as a YC-backed startup developing an in vivo tumor editing platform for glioblastoma.
QB3 · Jan 2025
QB3 announced a $100K proof-of-concept award to Kopra Bio after a December 2024 pitch session, with CEO Andrew Bartynski and co-founder Alexander Haddad leading the effort.